Is Celanese (CE) overvalued or fairly valued?

MarketChacha shows Celanese's valuation in context — a forward P/E of about 7.5, a price-to-book of about 1.3 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Celanese's revenue?

Celanese reported revenue of $9.5B for FY2025, with net profit of $-1.2B, per official filings.

What is the share price of Celanese (CE)?

Celanese last traded at $48.25 (+4.0% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Celanese

CE · NYSE · Materials · United States

$48.25+4.0%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 7:27 PM

Snapshot

TickerCE

ExchangeNYSE

SectorMaterials

IndustryChemicals

CountryUnited States

Employees11,000

HeadquartersIrving, United States

Market cap$5.3B

P/B1.3

Volume1.25M

Websitewww.celanese.com

Filings tracked6

About Celanese

Celanese Corporation produces and sells engineered polymers worldwide. It operates through Engineered Materials and Acetyl Chain segments. The company offers ethylene acrylic elastomers, ethylene vinyl acetate pharmaceutical grade copolymers, liquid crystal polymers, long-fiber reinforced thermoplastics, nylon and polypropylene compounds and formulations, polyoxymethylene, ultra-high molecular weight polyethylene, and thermoplastic elastomers, polyesters, and vulcanizates for use in appliance, automotive, construction, consumer apparel, consumer electronics, electrical, energy storage, filtration equipment, industrial, medical, and telecommunication applications. It also provides acetic acid and anhydride, acetate flakes and tows, butyl acetates, emulsion polymers, ethyl acetates, ethylene vinyl acetate resins and compounds, formaldehydes, redispersible powders, and vinyl acetate monomers for use in adhesives, automotive parts, coatings, consumer goods, external thermal insulation composite systems, films, filtration, flexible packaging, food and beverage, food packaging, inks, lamination, lubricants, paints, paper finishing, pharmaceuticals, plasticizers, plasters and renders, solvents, textiles, and tiling applications. The company offers its products under the Amcel, AOPlus, Ateva, Avicor, Celanese, Celanex, Celanyl, Celcon, Celstran, Celvolit, Clarifoil, Crastin, Dur-O-Set, Dytron, ECOMID, EcoVAE, Elotex, Factor, Flexbond, Forprene, FRIANYL, Fortron, Geolast, GHR, GUR, Hostaform, Hytrel, Laprene, Melinex, MetaLX, Mowilith, MT, Mylar, NILAMID, Nylfor, OmniLon, Pibifor, Pibiter, Polifor, Resyn, Rynite, Santoprene, SlideX, Sofprene, Sofpur, Talcoprene, Tarnoform, Tecnoprene, TufCOR, Tynex, Vamac, VAntage, Vectra, Vinac, Vinamul, VitalDose, Zenite, and Zytel brands. It sells its products directly to customers and through distributors; and original equipment manufacturers and suppliers. Celanese Corporation was founded in 1912 and is headquartered in Irving, Texas.

Profile as reported by Yahoo Finance.

Who owns it

Insiders0.4%
Institutions99.6%
Public & other0.0%

617 institutional holders

As reported by Yahoo Finance.

Top holders

Dodge & Cox Inc.13.99%
Blackrock Inc.11.94%
Vanguard Portfolio Management LLC5.72%
Vanguard Capital Management LLC4.51%
Capital Research Global Investors4.28%
State Street Corporation3.61%
Federated Hermes, Inc.3.45%
Fuller & Thaler Asset Management Inc.3.39%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

Forensic scorecard

Margin has compressed by about 30.0 points over the period — profitability is trending down.

Net margin trend17.8% → -12.2%

Margin has compressed by about 30.0 points over the period — profitability is trending down.

Return on equity-28.8%

Latest ROE of -28.8% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $2.7B · EPS 1.77

Est. earnings growth +31.8%

Next fiscal year

Rev $10.1B · EPS 6.42

Est. earnings growth +6.2%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$35.1352-wk range$70.70

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Market cap

$5.3B

Day change

+4.0%

Fwd P/E

7.5

P/B

1.3

Div yield

0.26%

Beta

0.76

Revenue (FY2025)

$9.5B

Net margin

-12.2%

ROE

-28.8%

Revenue CAGR (2y)

-6.5%

EPS (FY2025)

-10.64

Net profit (FY2025)

$-1.2B

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about CE

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$9.5B	$-1.2B	-10.64	-12.2%	-28.8%
FY2024	$10.3B	$-1.5B	-14.11	-15.0%	-30.1%
FY2023	$10.9B	$1.9B	17.76	17.8%	27.5%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$2.3B	$44.0M	0.40	1.9%
2025Q3	$2.4B	$-1.4B	-12.39	-56.1%
2025Q2	$2.5B	$199.0M	1.81	7.9%
2025Q1	$2.4B	$-24.0M	-0.22	-1.0%
2024Q3	$2.6B	$113.0M	1.03	4.3%
2024Q2	$2.7B	$155.0M	1.41	5.8%
2024Q1	$2.6B	$121.0M	1.10	4.6%
2023Q3	$2.7B	$951.0M	8.69	34.9%
2023Q2	$2.8B	$220.0M	2.01	7.9%
2023Q1	$2.9B	$91.0M	0.83	3.2%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Other events
SEC6/10/2026material
10-Q filing
SEC5/6/2026
8-K — Results of operations, Exhibits
SEC5/5/2026material
8-K — Reg FD disclosure, Exhibits
SEC5/5/2026material
8-K — Executive/director change, Exhibits
SEC4/20/2026material
8-K — Shareholder vote results, Exhibits
SEC4/17/2026material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.